The following video is part of our "Motley Fool Conversations" series, in which advisor Charly Travers and analyst Jason Moser discuss topics around the investing world.
Gilead Sciences is a world-class drug company that has created tremendous value for shareholders with a stock that's up 5 times over the past decade. The company, best known for its work in HIV drug development, is trying to branch out in another important anti-viral market: the treatment of hepatitis C. Gilead's recent clinical trial data on HCV drug GS-7977 was poorly received, sending the stock down 20%. Is now the time to buy?
Every now and again, we come across a stock that has us so excited we can hardly contain our investing enthusiasm. We've uncovered one such pick with so much promise that we've dubbed it "The Motley Fool's Top Stock for 2012." We've created a special free report for investors to uncover this soon-to-be rock star. The report highlights a company that is revolutionizing commerce in Latin America, and you can get instant access to the name of this company by clicking here to download it now.
